With growing pressures of increasing success rates for FDA approved biomarkers as well as companion diagnostics tests has seen an outgrowth in drug discovery companies to invest in novel strategies for biomarker discovery.
The major challenges faced in securing these approvals include identifying clinical relevance in the context of therapeutic targets and novel technologies to measure disease activity, reproducibility, variability issues- and finally translation of discoveries to FDA approved clinical tests.
The 3rd Annual Biomarker Conference takingplace on the 8th and 9th of February 2018, in San Diego-CA, USA, aims to gather experts from pharma, bio-pharma companies and research institutes to discuss current challenges and opportunities in therapeutic biomarkers, CDx, regulations, reimbursement models and disease specific applications of biomarkers.
This event is co-located with our 3rd Annual Genome Editing & Engineering Conference and 3rd Annual NGS Data Analysis and Informatics Conference.
0 DAY EVENT
0 Hours of Networking